RxDoctor Payments Data

Mark English, MD

Internal Medicine · Port Sanilac, MINPI 1699706929

Payments from drug & device makers

$690in general payments, 2019–2025

Across 35 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Braeburn Inc.$148
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$100
  • Novo Nordisk$76
  • AbbVie$67
  • Indivior Inc.$63
  • Novartis$52
  • plus $185 from 9 others

What the payments were for

  • Food & beverage$690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$690 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$47,964
Medicare patients
100
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$56,081
RybelsusSemaglutide15$27,194
Breo ElliptaFluticasone/Vilanterol17$15,079
TrulicityDulaglutide11$11,266
Combivent RespimatIpratropium/Albuterol Sulfate12$9,806
SymbicortBudesonide/Formoterol Fumarate17$7,799
MyrbetriqMirabegron12$6,324
TradjentaLinagliptin11$5,911
Novolog FlexpenInsulin Aspart26$5,117
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,665
Atorvastatin Calcium268$3,584
Ventolin HfaAlbuterol Sulfate37$2,631
Omeprazole188$2,607
Tamsulosin Hcl115$2,388
Pravastatin Sodium93$2,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$56,08145 claims
Novo NordiskRybelsus$76$27,19415 claims
Lilly USA, LLCTrulicity$16$11,26611 claims
AstraZenecaSymbicort$32$7,79917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Port Sanilac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →